BioPharmSignal logoBioPharmSignal

Biotech News

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

Adaptive Biotechnologies (ADPT)Adaptive Biotechnologies2026-06-25 13:46 ESTFinancing

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to $25 million of common stock to reduce potential dilution Remaining capital to be used

Open original release

Related news

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

View all latest news

Adaptive Biotechnologies

Adaptive Biotechnologies is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ADPTAdaptive Biotechnologies2026-06-26 08:45 EST

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

ADPTAdaptive Biotechnologies2026-06-26 08:45 EST

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

ADPTAdaptive Biotechnologies2026-06-26 08:45 EST

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

ADPTAdaptive Biotechnologies2026-06-26 08:45 EST

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

ADPTAdaptive Biotechnologies2026-06-26 08:45 EST

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States